Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

The postoperative pain management market is witnessing steady growth, driven by the rising number of surgical procedures globally and increasing awar ...